JNJ

167.69

-0.73%↓

ABT

126.13

+0.59%↑

MDT

92.38

+0.63%↑

ELV.US

292.1

+1.42%↑

VEEV

290.19

+0.36%↑

JNJ

167.69

-0.73%↓

ABT

126.13

+0.59%↑

MDT

92.38

+0.63%↑

ELV.US

292.1

+1.42%↑

VEEV

290.19

+0.36%↑

JNJ

167.69

-0.73%↓

ABT

126.13

+0.59%↑

MDT

92.38

+0.63%↑

ELV.US

292.1

+1.42%↑

VEEV

290.19

+0.36%↑

JNJ

167.69

-0.73%↓

ABT

126.13

+0.59%↑

MDT

92.38

+0.63%↑

ELV.US

292.1

+1.42%↑

VEEV

290.19

+0.36%↑

JNJ

167.69

-0.73%↓

ABT

126.13

+0.59%↑

MDT

92.38

+0.63%↑

ELV.US

292.1

+1.42%↑

VEEV

290.19

+0.36%↑

Search

Novartis AG

Open

116.49 -0.98

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

116.09

Max

117.72

Belangrijke statistieken

By Trading Economics

Inkomsten

418M

4B

Verkoop

660M

14B

K/W

Sectorgemiddelde

16.639

38.156

EPS

2.42

Dividendrendement

3.5

Winstmarge

28.18

Werknemers

75,883

EBITDA

-5.8B

4.9M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-5.02% downside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.50%

2.50%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-18B

221B

Vorige openingsprijs

117.47

Vorige sluitingsprijs

116.49

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Novartis AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 jul 2025, 14:26 UTC

Winsten

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17 jul 2025, 06:49 UTC

Winsten

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17 jul 2025, 05:41 UTC

Winsten

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

11 jun 2025, 08:25 UTC

Acquisities, Fusies, Overnames

EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio

17 jul 2025, 11:36 UTC

Marktinformatie

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17 jul 2025, 11:26 UTC

Marktinformatie

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17 jul 2025, 07:14 UTC

Marktinformatie

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17 jul 2025, 07:02 UTC

Marktinformatie
Winsten

Novartis's Results Look Impressive -- Market Talk

17 jul 2025, 05:09 UTC

Winsten

Novartis 2Q Sales Grew 11% at Constant Currency

17 jul 2025, 05:08 UTC

Winsten

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17 jul 2025, 05:06 UTC

Winsten

Novartis: Mehta's Appointment Is Effective March 2026

17 jul 2025, 05:05 UTC

Winsten

Novartis: Harry Kirsch Retires After 22 Years With Company

17 jul 2025, 05:05 UTC

Winsten

Novartis Names Mukul Mehta as CFO

17 jul 2025, 05:04 UTC

Winsten

Analysts Saw Novartis 2Q Net Profit at $3.815B

17 jul 2025, 05:04 UTC

Winsten

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

17 jul 2025, 05:04 UTC

Winsten

Analysts Saw Novartis 2Q Sales at $14.17B

17 jul 2025, 05:04 UTC

Winsten

Novartis 2Q Core Operating Profit $5.925B

17 jul 2025, 05:04 UTC

Winsten

Novartis 2Q Oper Pft $4.86B

17 jul 2025, 05:03 UTC

Winsten

Novartis 2Q Sales $14.05B

17 jul 2025, 05:01 UTC

Winsten

Novartis: Buyback to Be Completed by End of 2027

17 jul 2025, 05:01 UTC

Winsten

Novartis Starting Buyback of Up to $10B

17 jul 2025, 05:01 UTC

Winsten

Novartis Backs 2025 Sales View

17 jul 2025, 05:01 UTC

Winsten

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

17 jul 2025, 05:01 UTC

Winsten

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

17 jul 2025, 05:00 UTC

Winsten

Novartis Raises 2025 Earnings View

17 jul 2025, 05:00 UTC

Winsten

Novartis AG 2Q Adj EPS $2.42

17 jul 2025, 05:00 UTC

Winsten

Novartis AG 2Q Net Pft $4B

17 jul 2025, 05:00 UTC

Winsten

Novartis AG 2Q EPS $2.07

9 jul 2025, 10:59 UTC

Marktinformatie

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

2 jun 2025, 14:17 UTC

Marktinformatie

Novartis's Pluvicto Delivers Positive Results in Third Late-Stage Trial -- Market Talk

Peer Vergelijking

Prijswijziging

Novartis AG Prognose

Koersdoel

By TipRanks

-5.02% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 112.05 USD  -5.02%

Hoogste 140.155 USD

Laagste 88 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novartis AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

0

Buy

3

Hold

1

Sell

Technische score

By Trading Central

N/A / 112.63Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.